A multicenter analysis of patients with invasive lobular carcinoma—the second most common histological subtype of invasive breast cancer in the U.S.—showed that, despite its prevalence, ILC is detected later and has worse outcomes than the predominant subtype of invasive breast cancer, known as invasive ductal carcinoma, or no special type.
The phase III PhALLCON trial met its primary endpoint, demonstrating that adult patients with newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Iclusig (ponatinib) plus reduced-intensity chemotherapy achieved higher rates of minimal residual disease-negative complete remission compared to imatinib.
Positive results from the phase II/III QUILT 3.032 trial studying N-803 (nogapendekin alfa inbakicept), a novel IL-15 superagonist complex, plus BCG in adults with non-muscle invasive bladder cancer carcinoma in situ with or without Ta/T1 papillary disease were published in NEJM Evidence.
An artificial intelligence blood testing technology developed and used by Johns Hopkins Kimmel Cancer Center researchers to successfully detect lung cancer in a 2021 study has now detected more than 80% of liver cancers in a new study of 724 people.
Researchers from Vanderbilt-Ingram Cancer Center discovered that T-cells recognizing the cardiac antigen α-myosin are the mechanism for immunotherapy-related myocarditis.
Researchers at the Keck School of Medicine of USC and the Cleveland Clinic Florida Research and Innovation Center have published studies focused on GRP78, a protein implicated in both COVID-19 and multiple types of cancer, and a drug that interferes with its effects.
Two new studies from researchers at Fred Hutchinson Cancer Center reveal how bacteria infiltrate tumors and could be helping tumors progress and spread. The research team also showed that the different microbial players in a tumor’s microbiome could influence how a cancer responds to treatment.
Researchers at Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy successfully trained a machine learning algorithm to predict, in hindsight, which patients with melanoma would respond to treatment and which would not, in a small study.
Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have developed an automated system to calculate metabolic tumor volume in diffuse large B-cell lymphoma. These findings could make it easier to calculate tumor volume for clinical trials and possibly patient care.
In a phase Ib trial, led by Naval Daver and Michael Andreeff at MD Anderson Cancer Center, researchers evaluated the combination of Venclexta (venetoclax) and idasanutlin in 56 patients with R/R AML who were unfit for chemotherapy. IDH1/2 and RUNX1 mutations were associated with higher composite complete remission rates of 50% and 45%, respectively, and were linked to therapy sensitivity.
